Defender gets CRL from FDA on motion sickness nasal gel
ST. LOUIS, Jan. 30, 2024 (GLOBE NEWSWIRE) -- Defender Pharmaceuticals, Inc. (the œCompany or œDefender), a privately held life sciences company based in St. Louis, today announced that the U.S....
PDUFA date of January 26th, 2024 Assigned Priority Review Status at the Request of the US NavySubmission based on five Phase III clinical trials, including overwhelmingly positive results from the -33...
Submission based on five Phase III clinical trials, including overwhelmingly positive results from the -33 Phase 3 studyAn estimated one in three adults will suffer motion sickness at some point1 ST....
ST. LOUIS, June 05, 2023 (GLOBE NEWSWIRE) -- Defender Pharmaceuticals, Inc. (the œCompany or œDefender), a privately held life sciences company based in St. Louis, today announced positive results...
Enforcement Report - Week of February 1, 2023
Actavis Lab's Generic Scopolamine Receives Approval in the U.S.
Riconpharma`s Generic Triazolam Receives Approval in US
Alkaloids Corporation, an Indian manufacturer specialized in sophisticated plant extraction technologies and their marketing, sales & regulatory partner, Transo-Pharm Handels-GmbH, Germany, decided to join hands with the aim to expand Alkaloids’ phytochemical product portfolio and global reach back in 2013. The partnership structure was set up in a way that enables Alkaloids to focus on production & quality excellence while Transo-Pharm focuses on the commercial side, supply chain and adding regulatory support.
Mylan Technologies` Generic Scopolamine Receives Approval in US